GammaDelta Therapeutics acquires Lymphact to advance their gamma delta (γδ) T-Cell platform into the clinic

Tissue Resident Gamma Delta T Cells for transformative Immunotherapies

Our unique and pioneering approach to targeted gamma delta T cell therapy could revolutionise immunotherapy for patients

Discover GammaDelta Therapeutics

GammaDelta Therapeutics’ innovative and unique approach to Immunotherapy has the potential to make a significant impact on the treatment of cancer and auto-immune diseases.

Gamma delta T cells are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathologies. The new company is focused on exploiting the unique characteristics of tissue derived gamma delta T cells.

Discover the Science

Strategic Partners

Taking ground-breaking research to a viable medicine or innovative modalities of treatment needs an experienced, passionate, dedicated team and the support of key partners. GammaDelta Therapeutics has built partnerships with some of the most prestigious Institutions in oncology, immune therapy and life science investment.